OSE Immunotherapeutics SA (EPA: OSE)

France flag France · Delayed Price · Currency is EUR
7.94
-0.06 (-0.75%)
Aug 30, 2024, 5:35 PM CET
183.57%
Market Cap 172.72M
Revenue 2.23M
Net Income -23.00M
Shares Out 21.75M
EPS -1.18
PE Ratio n/a
Forward PE 2.34
Dividend n/a
Ex-Dividend Date n/a
Volume 141,964
Open 8.00
Previous Close 8.00
Day's Range 7.85 - 8.25
52-Week Range 2.83 - 8.63
Beta 0.91
Analysts n/a
Price Target n/a
Earnings Date Sep 27, 2024

About OSE Immunotherapeutics

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 55
Stock Exchange Euronext Paris
Ticker Symbol OSE
Full Company Profile

News

There is no news available yet.